Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Intangibles for 9 consecutive years, with $197.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Intangibles rose 10.67% to $197.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $197.0 million, a 10.67% increase, with the full-year FY2025 number at $197.0 million, up 10.67% from a year prior.
  • Intangibles was $197.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $172.9 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $197.0 million in Q4 2025 to a low of $130.8 million in Q4 2021.
  • A 5-year average of $160.1 million and a median of $161.9 million in 2022 define the central range for Intangibles.
  • Peak YoY movement for Intangibles: grew 25.22% in 2022, then fell 0.69% in 2023.
  • Ultragenyx Pharmaceutical's Intangibles stood at $130.8 million in 2021, then grew by 25.22% to $163.8 million in 2022, then rose by 1.52% to $166.3 million in 2023, then grew by 7.05% to $178.0 million in 2024, then grew by 10.67% to $197.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Intangibles are $197.0 million (Q4 2025), $172.9 million (Q3 2025), and $174.7 million (Q2 2025).